Nuwellis (NUWE) announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,415,021 on September 16, 2025, based on Application No. 18/298,860. The patent relates to the use of one or more hemolysis sensors with extracorporeal blood filtration systems-such as ultrafiltration therapy and continuous renal replacement therapy-to help detect and localize red blood cell destruction occurring within or around the circuit. The intellectual property supports Nuwellis’ pediatric device, Vivian, in development and future platform innovation.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUWE:
- Nuwellis Secures NIH Grant for Pediatric Device Development
- Nuwellis announces NIH awarded $3M multi-year grant to KBT
- Nuwellis introduces 24-hour circuit for Aquadex therapy in the U.S.
- Nuwellis Announces At The Market Offering Agreement
- Nuwellis, Inc. Earnings Call: Challenges and Strategic Initiatives